HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 215 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,875,273 | +28.7% | 35,815 | 0.0% | 0.01% | 0.0% |
| Q1 2024 | $1,456,954 | +151.3% | 35,815 | +128.4% | 0.01% | +150.0% |
| Q4 2023 | $579,681 | +17.4% | 15,684 | +21.3% | 0.00% | 0.0% |
| Q3 2023 | $493,926 | +1.4% | 12,930 | -4.3% | 0.00% | 0.0% |
| Q2 2023 | $487,125 | +20.0% | 13,505 | +26.9% | 0.00% | 0.0% |
| Q1 2023 | $406,000 | -20.9% | 10,642 | +17.9% | 0.00% | -33.3% |
| Q4 2022 | $513,579 | +2.3% | 9,026 | -28.9% | 0.00% | 0.0% |
| Q3 2022 | $502,000 | +17.8% | 12,689 | +31.2% | 0.00% | +50.0% |
| Q2 2022 | $426,000 | -78.9% | 9,673 | -79.6% | 0.00% | -81.8% |
| Q4 2020 | $2,022,000 | -10.2% | 47,332 | -44.8% | 0.01% | -15.4% |
| Q3 2020 | $2,252,000 | -5.0% | 85,700 | -3.1% | 0.01% | -13.3% |
| Q2 2020 | $2,371,000 | -34.9% | 88,453 | -56.3% | 0.02% | -44.4% |
| Q1 2020 | $3,642,000 | – | 202,457 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
| BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
| DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
| SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
| First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
| Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
| Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
| Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |